vimarsana.com
Home
Live Updates
Adagrasib Meets Primary Endpoint Among Individuals with KRAS
Adagrasib Meets Primary Endpoint Among Individuals with KRAS
Adagrasib Meets Primary Endpoint Among Individuals with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC
The positive results in both progression-free survival and overall response rate were endorsed in a confirmatory study.
Related Keywords
Bristol Myers Squibb ,
Abderrahim Oukessou ,
Prescription Drug User Fee Act ,
Blinded Independent Central Review ,
Trial Evaluating ,
Meets Primary Endpoint ,
Progression Free Survival ,
Mutated Locally Advanced ,
Metastatic Non Small Cell ,
Bristol Myers ,